Halozyme Therapeutics Inc 1HALO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- €96.66
- Day Range
- €88.72–93.50
- 52-Week Range
- €51.30–103.00
- Bid/Ask
- €96.76 / €99.12
- Shares Outstanding
- 113.50M
- Market Cap
- $10.89B
- Volume/Avg
- 265 / 70
Key Statistics
- Price/Earnings (Normalized)
- 20.89
- Price/Sales
- 8.23
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- 2.87%
Company Profile
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 423
- Website
- https://www.halozyme.com
Valuation
|
Metric
|
1HALO
|
|---|---|
Price/Earnings (Normalized) | 20.89 |
Price/Book Value | 87.07 |
Price/Sales | 8.23 |
Price/Cash Flow | 14.31 |
Price/Earnings
1HALO
Financial Strength
|
Metric
|
1HALO
|
|---|---|
Quick Ratio | 1.99 |
Current Ratio | 2.71 |
Interest Coverage | 29.73 |
Quick Ratio
1HALO
Profitability
|
Metric
|
1HALO
|
|---|---|
Return on Assets (Normalized) | 29.07% |
Return on Equity (Normalized) | 280.50% |
Return on Invested Capital (Normalized) | 33.40% |
Return on Assets
1HALO
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|<#DMZ@G | LOCK|#bP$ | $128B | |||
| Moderna Inc
MRNA
| LOCK|mhFX#!? | LOCK|y@ | $76B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|mDRwR$ | LOCK|gY>& | $76B | |||
| argenx SE ADR
ARGX
| LOCK|W?kwg! | LOCK|Dj | $57B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|QTlYFS | LOCK|Rk | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|fXMdRV | LOCK|vn?!J | $29B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|gbkjj&$S | LOCK|QHM@ | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|L>%BT@ | LOCK|jG> | $24B | |||
| Incyte Corp
INCY
| LOCK|s&$qlQz | LOCK|&& | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|X!cD?K | LOCK|g$X | $15B |
United States